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Abstract 24 
Pan-viral DNA array (PVDA) and high-throughput sequencing (HTS) are useful tools to 25 
identify novel viruses of emerging diseases. However, both techniques have difficulties to 26 
identify viruses in clinical samples because of the host genomic nucleic acid content 27 
(hg/cont). Both propidium monoazide (PMA) and ethidium bromide monoazide (EMA) 28 
have the capacity to bind free DNA/RNA, but are cell membrane-impermeable. Thus, 29 
both are unable to bind protected nucleic acid such as viral genomes within intact virions. 30 
However, EMA/PMA modified genetic material cannot be amplified by enzymes. In 31 
order to assess the potential of EMA/PMA to lower the presence of amplifiable hg/cont in 32 
samples and improve virus detection, serum and lung tissue homogenates were spiked 33 
with porcine reproductive and respiratory virus (PRRSV) and were processed with 34 
EMA/PMA. In addition, PRRSV RT-qPCR positive clinical samples were also tested. 35 
EMA/PMA treatments significantly decreased amplifiable hg/cont and significantly 36 
increased the number of PVDA positive probes and their signal intensity compared to 37 
untreated spiked lung samples. EMA/PMA treatments also increased the sensitivity of 38 
HTS by increasing the number of specific PRRSV reads and the PRRSV percentage of 39 
coverage. Interestingly, EMA/PMA treatments significantly increased the sensitivity of 40 
PVDA and HTS in two out of three clinical tissue samples. Thus, EMA/PMA treatments 41 
offer a new approach to lower the amplifiable hg/cont in clinical samples and increase the 42 
success of PVDA and HTS to identify viruses. 43 
Keywords: DNA array; high-throughput sequencing; virus identification; porcine 44 
reproductive and respiratory syndrome virus; PRRSV; propidium monoazide; PMA; 45 
ethidium bromide monoazide; EMA.  46 
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1.0 Introduction 47 
 48 
The emergence of new viral diseases represents a constant threat to human and animal 49 
health. Fortunately, in the past decade, accesses to novel technologies have improved the 50 
detection and identification of unknown viruses in clinical samples. Most of these novel 51 
virus identification processes are based on viral genome detection using new technologies 52 
like pan-viral DNA microarrays (PVDA) and high-throughput sequencing (HTS).  53 
 54 
The first PVDA, which contained 1,600 oligonucleotides probes targeting highly 55 
conserved DNA sequences of 140 distinct selected viral genomes, was reported in 2002 56 
[1]. Since then, the PVDA has been further developed and includes, in its latest version, 57 
36,000 oligonucleotides probes targeting approximately 1,500 distinct viral genomes [2]. 58 
This technology has been used to rapidly identify viruses involved in human illness, like 59 
severe acute respiratory syndrome (SARS) [3], and in animal diseases [2]. Use of this 60 
technology is of interest as the results can be generally obtained within a day and does 61 
not require other advanced technologies for results interpretation [2]. However, PVDA is 62 
dependent on the selected probes it contains and their tolerance to nucleotide mismatch 63 
during the DNA hybridization process required for the detection and identification of 64 
viruses in a clinical sample [4].  65 
 66 
Decreasing costs has made HTS technology more accessible and consequently, its use in 67 
identifying novel or unknown viruses affecting humans, animals or plants has increased 68 
[5-7]. It has even led to the discovery of unforeseen viruses in clinical samples [8]. 69 
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Metagenomic sequencing has the potential to determine the entirety of the nucleic acid 70 
sequences within a sample, including viral nucleic sequences of interest [9]. The 71 
metagenomic DNA sequences obtained with HTS are then compared to a genomic 72 
database in order to identify the nucleic acid sequences associated with known viruses 73 
[10]. One major benefit to metagenomic sequencing of clinical samples is the potential to 74 
detect and assemble the genome of novel viruses [11].  75 
 76 
Although both PVDA and HTS have led to the discovery of new viruses in the last years, 77 
especially from isolated viruses, both techniques are negatively impacted by the presence 78 
of nucleic acid found in clinical samples, mainly host genomic DNA/RNA [10, 12]. The 79 
high host to viral DNA ratio in extracted clinical samples greatly decreases PVDA 80 
sensitivity since most of the amplified labeled DNA corresponds to host DNA [12]. For 81 
sequencing, depending on the method of tissue preparation and viral particle 82 
concentration, again the high host to viral DNA ratio decreases the sensitivity of the 83 
technology [13]. As more reads must be obtained in order to detect the presence of a virus 84 
in a clinical sample, this can increase sequencing costs and lower throughput while 85 
creating a potential bioinformatics bottleneck. Thus, in order to improve viral detection in 86 
clinical samples with HTS and PVDA, the levels of host genomic DNA must be lowered. 87 
This is generally done by treating samples with a combination of ultracentrifugation, 88 
filtration and/or nuclease treatment (typically DNase and/or RNase treatment) [9, 14]. As 89 
these methods can introduce bias in viral identification (9) the development of alternative 90 
methods to lower host genomic material in clinical samples is of interest.  91 
 92 
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Ethidium bromide monoazide (EMA) and its analog propidium monoazide (PMA), when 93 
combined with PCR, allow the quantification of living cells such as bacteria [15-18]. 94 
Both are azide-bearing, DNA/RNA-intercalating dyes that only cross damaged lipid 95 
membrane barriers. Both dyes can bind and covalently crosslink DNA/RNA when the 96 
azide group is converted to a highly reactive nitrene radical upon exposure to bright 97 
visible light. Thereafter, they are easily inactivated and the unbound inactivated 98 
EMA/PMA remains free in solution. EMA/PMA-generated DNA/RNA cross-linking 99 
strongly inhibits reverse-transcription and PCR amplification of the EMA/PMA modified 100 
genomes while unmodified genomes from presumptively living bacteria (which possesses 101 
intact membranes) can be amplified [17]. Interestingly, EMA/PMA treatments have been 102 
used to distinguish infectious from non-infectious viruses such as Hepatitis A virus, 103 
coxsakievirus, echovirus, norovirus and poliovirus, suggesting that intact virus particles 104 
have the potential to protect their genetic material from EMA/PMA chemicals [19].   105 
 106 
In theory, EMA/PMA could be used to prevent host genomic amplification during the 107 
PCR steps that are conducted within PVDA and HTS assays, while the viral genome 108 
within intact virions are inaccessible to the dyes during treatment before amplification. 109 
The main objective of this study was to determine if EMA or PMA treatments can 110 
increase the efficacy of PVDA and HTS to detect viruses in clinical samples.   111 
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2.0 Materials and methods 112 
 113 
2.1. Cell and virus strains 114 
 115 
MARC-145 cells were maintained as described previously and were used for virus 116 
production [20]. The Porcine reproductive and respiratory syndrome virus (PRRSV) 117 
strain used to spike tissue and sera samples was the IAF-Klop reference strain [21]. The 118 
PRRSV IAF-Klop strain stock was obtained following three cycles of freeze-thaw of 119 
PRRSV MARC-145 infected cells. Afterward, the virus stocks were maintained at -70°C 120 
until needed. The infectious dose of the stocks was calculated from MARC-145 infected 121 
cells by the Kärber method as described previously [22]. Virus titers were expressed in 122 
tissue culture infectious dose 50% per mL (TCID50/mL).  123 
 124 
2.2 PRRSV spiked tissues and positive clinical samples 125 
 126 
Lung and blood samples were collected from negative control and PRRSV 127 
experimentally infected piglets. Animals care was done according to the guidelines of the 128 
Canadian Council of Animal Care and the protocol approved by the Institutional Animal 129 
Care Committee (Protocol 12-Rech-1669). The PRRSV strain involved in this infection 130 
was PRRSV FMV12-1425619 (GenBank accession number KJ1888950). Sera of non-131 
infected and infected piglets were collected at different time post-infection (pi) and kept 132 
at -70°C until needed. Viral load in samples was determined with a specific PRRSV RT-133 
qPCR assay as previously described [8]. Lung samples were collected at necropsy at 28 134 
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days pi and stored at -70°C until needed. Three infected lung samples (PRRSV titers: 1) 135 
4929, 2) 4336 and 3) 9408 TCID50/g) were selected. Two sera samples were selected 136 
from PRRSV positive clinical sera samples (PRRSV titers of 1) 1059 and 2) 7413 137 
TCID50/mL) submitted to the Molecular Diagnostic Laboratory (MDL) of the University 138 
of Montreal were selected and stored at -70°C until needed.  PRRSV negative swine lung 139 
samples or PRRSV negative swine sera samples were spiked with a known quantity of 140 
the PRRSV IAF-Klop strain to a final concentration of either 5,000 TCID50/mL or 50,000 141 
TCID50/mL. Lung tissue samples (spiked samples or PRRSV positive clinical samples; 142 
100 mg of tissue in 1 mL of PBS with glass beads) were homogenized twice for five 143 
minutes in a Mini BeadBeater 96 Homogenizer, centrifuged one min at 10 000 rpm in a 144 
table top centrifuge and kept at 4°C until used. Serum samples (spiked samples or 145 
PRRSV positive clinical samples) were kept at 4°C once thawed.  146 
 147 
2.3 Samples processing 148 
 149 
2.3.1 Ultracentrifugation 150 
 151 
Lung tissue homogenate and serum samples (spiked with PRRSV or clinical samples) 152 
were ultracentrifuged for 3h at 25,000 rpm in a Sorvall TH-641 swinging bucket rotor at 153 
4°C through 1mL of a 20% sucrose cushion in TNE buffer (20 mM Tris-HCl (pH 8.0), 154 
150 mM NaCl and 2 mM EDTA). The virus pellets were re-suspended in TNE buffer to 155 
the initial sample volume prior to ultracentrifugation. Non-ultracentrifugated sample 156 
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aliquots were kept at 4°C for the duration of the ultracentrifugation step. Clinical samples 157 
(lung tissue and serum) were assessed by ultracentrifugation only.  158 
 159 
2.3.2. Ethidium bromide monoazide and propidium monoazide treatments 160 
 161 
EMA and PMA (Biotium, Hayward, CA) were reconstituted according to manufacturer’s 162 
recommendation. Stock solutions were then diluted in RNase-free water to a working 163 
concentration of 2 mM. Both stock and working solutions were kept at -20°C until used. 164 
Lung tissue homogenates with and without ultracentrifugation (spiked or clinical 165 
samples) and sera samples (spiked or clinical samples) were subsequently treated with 166 
EMA (final concentrations of 100 µM), PMA (final concentrations of 100 µM), or with 167 
an equivalent volume of water. Treated samples were then incubated in the dark for five 168 
minutes at room temperature, five minutes on ice, and then exposed during ten minutes to 169 
two 500 watt halogen light sources (at a distance of 20 cm from the light source). Micro-170 
centrifuge tubes were kept on ice during light exposure to avoid excessive heating.  171 
 172 
2.4. Total nucleic acid extraction  173 
 174 
Following treatments, total DNA and RNA were extracted using a phenol-chloroform-175 
isoamyl alcohol. Briefly, 200 µL of a phenol solution at pH 7.6-7.8 (UltraPure™ buffer-176 
saturated phenol; Invitrogen, Burlington, ON), 200 µL of molecular grade chloroform 177 
(Fisher scientific, Ottawa, ON) and 20 µL of isoamyl alcohol (Fisher scientific) were 178 
added to each sample. Samples were then homogenized and centrifuged in a table-top 179 
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microcentrifuge for 1 min at 13,000 rpm. The supernatant was kept and assessed for a 180 
second phenol-chloroform step. Finally, the supernatant was treated twice with 200 µL of 181 
chloroform and total DNA and RNA precipitated by adding 500 µL of ethanol and 20 µL 182 
of sodium acetate (3M, pH 5.2) and incubation at -70°C overnight followed by 183 
centrifugation for 30 min at 4°C in a table-top microcentrifuge at 13,000 rpm. The pellet 184 
representing total nucleic acid was resuspended in 50 µL of RNase-free water and stored 185 
in a freezer at -70°C until used.  186 
 187 
2.5. PRRSV and host genome quantification by qPCR and RT-qPCR 188 
 189 
PRRSV and swine β-Actin (representing swine host genomic DNA) were quantified in 190 
extracted DNA/RNA by RT-qPCR and qPCR, respectively. Equal sample volumes were 191 
used for each test to ensure comparable results. PRRSV was quantified in DNA/RNA 192 
extracted from tested samples using the commercial EZ-PRRSV™ MPX 4.0 Real Time 193 
RT-PCR kit (Tetracore, Rockville, Maryland, USA), following the manufacturer’s 194 
recommendations. The β-actin quantification was done by qPCR using the SsoFast™ 195 
EvaGreen® Supermix kit (Bio-rad, Hercules, CA, USA) in order to evaluate host genome 196 
in spiked and clinical samples following each treatment. Samples were diluted in RNase 197 
free water (1:16) prior to β-actin qPCR tests. The PCR amplification program for β-actin 198 
quantification consisted of an enzyme activation step of 3 min at 98°C followed by 40 199 
cycles of a denaturing step (2 s at 98°C) and an annealing/extension step (5 s at 58°C) 200 
using the following primers: forward primer (5’- ATCTTCATGAGGTAGTCGGTCAGG 201 
- 3’) and reverse primer (5’- ACCACTGGCATTGTCATGGACTCT -3’). Both primers 202 
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were selected to achieve amplification efficiency between 90 and 110% (data not shown) 203 
and were designed from the NCBI GenBank mRNA sequences using web-based software 204 
primerquest from Integrated DNA technologies. All amplification steps were done on a 205 
Bio-Rad CFX 96 apparatus with results expressed as Ct values.  206 
 207 
2.6. DNA/RNA samples amplification 208 
 209 
Following treatment and extraction, total nucleic acid samples used for all experiments 210 
(i.e. both array detection and PMA/EMA treatment) were amplified using a modified 211 
random PCR protocol [1, 2]. Random-amplified samples for PVDA testing were spiked 212 
with 225 pg of purified pUC19 plasmid DNA and used both as a positive control and 213 
localization marker on array slides.  214 
 215 
2.7. DNA array  216 
 217 
2.7.1 DNA array development 218 
 219 
Probe sequences targeting PRRSV American strains were selected from the PRRSV 220 
probes used on the ViroChip developed by Wang et al. (2002)[1] and were deduced from 221 
sequences alignment of full and partial PRRSV genomic sequences gathered from the 222 
National Center for Biotechnology Information (NCBI) GenBank database using 223 
Geneious pro software, version 5.6.6 (Biomatters, Auckland, New Zealand 224 
[http://www.geneious.com/]). The PRRSV homology of candidate probes was verified 225 
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with BLASTN. Each selected oligonucleotide probe (70-mers) was unique and was 226 
targeting specific PRRSV conserved regions. Reverse and forward sequences of 17 227 
conserved regions were selected for the PRRSV genotype 2 strains. Two probes were 228 
also selected to target a specific region of pUC19 plasmid DNA as an array positioning 229 
control and one probe was selected as a negative hybridization control. A total of 37 230 
probes were selected and were synthesized by Eurofins MWG Operon (Huntsville, AL, 231 
USA). These probes are reported in the Gene Expression Omnibus (GEO) NCBI database 232 
(accession number GSE62910). DNA array spotting was done at the National Research 233 
Council Canada, as previously described [23].  234 
 235 
2.7.2. DNA array hybridization and analysis 236 
 237 
After RT and PCR random-amplification steps, PCR products were incubated with 238 
aminoallyl (aa)-dUTP (Invitrogen, Burlington, ON, Canada) in the presence of Klentaq 239 
(Clontech) as previously described [1, 2]. The generated aa-DNA was purified with the 240 
QIAquick PCR purification kit (QIAGEN, Toronto, ON, Canada), re-suspended in 30 µL 241 
of RNase-free water and supplemented with 3 µL of 1M sodium bicarbonate. Thereafter, 242 
the aa-DNA was incubated for 1h in the presence of 1:10 DMSO-reconstituted Cy3 243 
Mono-Reactive Dye (GE Healthcare Life Sciences, Pittsburgh, PA, USA). Labeled DNA 244 
was then purified using a QIAquick PCR purification kit and assessed for quality using a 245 
NanoDrop 1000 spectrophotometer (Fisher Scientific, Toronto, ON, Canada).  246 
 247 
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Microarray slides were pre-hybridized at 50°C for 1h with 85.5 µL of DIG easy Hyb 248 
buffer (Hoffmann-La Roche Limited, Mississauga, ON, Canada) supplemented with 4.5 249 
µL of 10% (w/v) bovine serum albumin (Invitrogen, Burlington, ON, Canada) under 250 
22mm x 60mm x 0.25mm Grace Bio-Labs Hybrislip™ coverslips (Sigma Aldrich, 251 
Oakville, ON, Canada). Subsequently, cover slips were removed by dipping the glass 252 
slides into 0.1x SSC (15mM NaCl, 1.5mM sodium citrate) and the slides dried by a quick 253 
centrifugation. Total Cy3-labeled DNA (typically 3 µg) was dried in a Speedvac (Fisher 254 
scientific) then suspended in 7 µL of DIG Easy Hyb buffer. Afterwards, the DNA was 255 
denatured for five min in a boiling water bath followed by five min of incubation on ice. 256 
Samples were hybridized overnight in a water bath at 50°C under 22 mm x 22 mm Grace 257 
Bio-Labs Hybrislip™ (Sigma Aldrich). Finally, coverslips were removed in 0.1x SSC, 258 
0.1% (V/V) sodium dodecyl sulfate (SDS) and the slides washed three times in 0.1x SSC, 259 
0.1% (v/v) SDS and once in 0.1x SSC for five minutes per wash. Hybridized arrays were 260 
imaged using a fluorescence scanner (ScanArray; Perkin Elmer, Mississauga, ON, 261 
Canada) and ScanArray software version 1.1. Fluorescent spot intensities were scanned at 262 
a laser fluorescent intensity of 80 to 100 and quantified using ScanArray software version 263 
1.1. DNA array fluorescent intensity results were analysed with Microsoft Excel™. The 264 
intensity of each spotted probe was compared to the average intensity of the two negative 265 
control spots. For a probe to be considered positive, the average of signal-to-noise 266 
fluorescence ratios of their duplicate spots had to be ≥ 2.0.  267 
 268 
2.8. High-throughput sequencing 269 
 270 
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The random amplified samples were end-repaired and A-tailed using KAPA High 271 
Throughput Library Preparation Kit with SPRI solution and Standard PCR Library 272 
Amplification/Illumina series (Kapa Biosystems, Wilmington, MA, USA). Illumina 273 
TruSeq HT dual indexed adapters (Illumina, SanDiego, CA, USA) were ligated to the 274 
amplified samples and the libraries were amplified with the KAPA kit. After the final 275 
cleanup, the quality of the libraries were assessed on High Sensitivity DNA Chips 276 
(Agilent, Santa Clara, CA, USA) using a 2100 BioAnalyzer (Agilent). Equal amounts of 277 
each library were pooled and sequenced on an Illumina MiSeq (2 x 300 paired-end reads, 278 
dual-indexed) at the Plateforme d'Analyses Génomiques de l'institut de Biologie 279 
Intégrative et des Systèmes de l'Université Laval (Quebec, QC, Canada). Raw sequencing 280 
reads were trimmed for the random amplification primers and mapped to the Sus scrofa 281 
genome v10.2 and the PRRSV IAF-Klop viral genome sequence using the gsMapper 282 
application of Newbler v2.9. 283 
 284 
2.9. Statistical analysis  285 
 286 
A parametric one-way ANOVA model, followed by Tukey’s Multiple Comparison tests 287 
(GraphPad PRISM Version 5.03 software) was used to determine if a statistically 288 
significant difference exists between the quantification of targeted genes (β-actin or 289 
PRRSV) for each treated and untreated samples, as evaluated by qPCR and RT-qPCR. A 290 
non-parametric one-way ANOVA model, followed by Dunn’s Multiple Comparison Test 291 
(GraphPad PRISM software), was used to determine if a statistically significant 292 
difference exists between the mean relative fluorescent intensity of each PRRSV 293 
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detection probe on the DNA array for each treated and untreated samples. The ratio of 294 
positive PRRSV reads compared to the total amount of reads following each treatment 295 
was analysed with a mixed linear model, with trial number as a random factor and 296 
treatment as a fixed factor, followed by Tukey’s Multiple Comparison tests (SAS version 297 
9.3 software, Cary, NC, USA). HTS results were also evaluated individually using chi-298 
square tests in order to determine if the odds to obtained positive PRRSV reads were 299 
different following each selected treatments, compared to the total amount of reads not 300 
related to PRRSV (GraphPad PRISM software). Finally, a Spearman’s non-parametric 301 
correlation was also used to evaluate the relation between the presence of DNA 302 
contaminant reads and positive PRRSV reads as well as the ratio of PRRSV reads and the 303 
PRRSV percent of coverage in HTS results (SAS version 9.3 software). Differences were 304 
considered statistically significant with a P<0.05, with the exception of chi-square tests 305 
results where only P<0.003 (P<0.05/15) were considered significant.   306 
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3.0. Results 307 
 308 
3.1. EMA or PMA treatment effects on host-genomic DNA and PRRSV detection in spiked 309 
samples 310 
 311 
In order to select an effective concentration for EMA and PMA treatment, a preliminary 312 
experiment was done with PRRSV spiked lung samples (5,000 TCID50/mL; data not 313 
shown) and a final EMA and PMA concentration of 100 µM was selected for the 314 
realisation of subsequent experiments. Using this concentration, the effect of EMA or 315 
PMA treatments on virus genome’s presence and host genomic DNA was further 316 
evaluated in tissue samples spiked with known quantities of PRRSV (5,000 TCID50/mL 317 
or 50,000 TCID50/mL) but also in serum samples spiked with the same PRRSV 318 
quantities. Results with lung homogenates spiked with both concentration of PRRSV 319 
indicate that EMA and PMA treatments significantly lowered PRRSV detection 320 
compared to non-treated samples (Fig. 1A; P<0.001 and P<0.05 respectively). However, 321 
PRRSV detection was more negatively affected following EMA treatment (Fig. 1A; 322 
P<0.01), indicating that PMA treatments have less negative impact on RT-qPCR PRRSV 323 
detection as observed in the preliminary experiment. Ultracentrifugation had a significant 324 
positive impact on PRRSV detection in lung tissue homogenates spiked with either 325 
concentration of PRRSV following EMA treatment (Fig. 1A; P<0.001). In lung tissue 326 
homogenates spiked only with the highest concentration of PRRSV, ultracentrifugation 327 
had also increased significantly PRRSV detection following no treatment and following 328 
PMA treatment (Fig. 1A; P<0.01 and P<0.05 respectively). In spiked serum samples, 329 
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only EMA treatment significantly decreased PRRSV detection (Fig. 1A; P<0.05). 330 
Ultracentrifugation significantly improved PRRSV detection in non-treated spiked sera 331 
samples (Fig. 1A; P<0.001) and significantly decreased PRRSV RT-qPCR detection in 332 
EMA treated spiked sera samples (Fig. 1A; P<0.001).  333 
 334 
Both EMA and PMA treatments, combined or not with ultracentrifugation, were equally 335 
efficient in lowering β-actin amplification in PRRSV spiked lung tissue homogenates 336 
(Fig. 1B; P<0.001). Ultracentrifugation of non-treated spiked lung tissue samples also 337 
slightly lowered β-actin amount (Fig. 1B; P<0.05). In spiked sera samples, β-actin was 338 
already at the limit of detection in untreated samples, which indicates that hg/cont is 339 
much lower in sera compared to lung tissue homogenates (Fig. 1B).  340 
 341 
 342 
3.2. DNA array sensitivity with EMA or PMA treated PRRSV spiked tissues. 343 
 344 
After nucleic acid extraction, random amplification and DNA labeling were done on each 345 
spiked samples and the fluorescence of each PRRSV probe was measured following the 346 
hybridization of labeled samples on DNA arrays and compared to the negative probe 347 
fluorescence intensity (see accession number GSE62910 in the GEO NCBI database for 348 
raw data). Surprisingly, probes signals intensity and positivity were varying between 349 
experiments. For lung samples spiked with PRRSV (5,000 TCID50/mL), a low number of 350 
slightly positive probes (probes relative signal intensity < 5) were detected in untreated 351 
samples (Fig. 2A). Interestingly, multiple probes with relative high fluorescence  352 
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intensity (>5) were detected following PMA treatment when combined with 353 
ultracentrifugation and were associated with a significantly higher number of positive 354 
probes compared to untreated samples with ultracentrifugation and the PMA treated 355 
samples without ultracentrifugation (Fig. 2A; P<0.001). In contrast, the fluorescence 356 
intensity of detected positive probes of EMA-treated lung homogenates spiked with 357 
PRRSV (5 000 TCID50/mL) were significantly lower than all other experimental groups, 358 
indicating a lower chance to detect positive probes following treatment with EMA 359 
(P<0.05; Fig. 2A).  360 
 361 
In lung samples spiked with a higher concentration of PRRSV (50,000 TCID50/mL), a 362 
small number of low intensity positive probes (fluorescence relative signal <5) or no 363 
positive probes (fluorescence relative signal <1) were detected in untreated samples (Fig. 364 
2B). A significant increase in the number of high intensity positive probes (fluorescence 365 
relative signal >5) were found in samples treated with PMA, with or without 366 
ultracentrifugation, when compared to untreated samples without ultracentrifugation (Fig. 367 
2B; P<0.001). Surprisingly, only a few positive probes were found in samples treated 368 
with ultracentrifugation and EMA, similar to untreated samples. However, the number 369 
and intensity of probes in samples treated with EMA without ultracentrifugation were 370 
significantly higher compared to untreated samples without ultracentrifugation 371 
(P<0.001).  372 
 373 
In spiked sera samples, it was interesting to observe that all experimental groups had 374 
large numbers of probes with high intensity fluorescence signal against PRRSV, 375 
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including untreated samples (Fig. 2C), indicating overall that all treatments 376 
(ultracentrifugation versus PMA/EMA) did not improve DNA array sensitivity when 377 
used with sera samples. Interestingly, PMA treatment compared to untreated sera reduced 378 
the PVDA sensitivity even if a high number of high intensity positive probes were 379 
observed in PMA treated sera (Fig. 2C; P<0.05).  380 
 381 
3.3. HTS efficiency with EMA or PMA treated PRRSV spiked tissues. 382 
 383 
DNA sequences obtained from sequencing experiments were compared to the swine 384 
mitochondrial (GenBank accession numbers NC_000845) and chromosomal genomic 385 
DNA sequences (GenBank accession numbers NC_010443-NC_010462) as well as the 386 
full genetic sequence of the PRRSV strain used in this study. All HTS reads associated 387 
with PRRSV sequence were also considered to evaluate the virus coverage obtained 388 
following each treatment combination.  389 
 390 
In two out of three experiments, PMA and EMA treated PRRSV spiked lung tissues 391 
(5,000 TCID50/mL) had a significant increase in the number of PRRSV reads when 392 
compared to untreated samples, as revealed by the chi-square analysis (Fig. 3A; 393 
P<0.001). A strong correlation was found between PRRSV percent of coverage and the 394 
higher number of reads following treatment (r=0.81, P<0.001), indicating that the 395 
increase in PRRSV coverage is related to the augmentation in PRRSV reads. However, 396 
when all three HTS experiments were combined together in the statistical analyses, no 397 
significant differences were obtained between the amount of PRRSV specific reads 398 
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against the total amount of reads (Fig. 3A; P=0.4358) or the PRRSV percentage of 399 
coverage (Fig. 3B; P=0.5585). Noteworthy, the experiment showing no improvement in 400 
the amount of PRRSV reads was associated with a higher level of hg/cont as revealed in 401 
Fig. 3C. In fact, a strong negative correlation was found between the ratio of PRRSV 402 
reads (number of PRRSV reads / total number of reads) and the ratio of host genomic 403 
reads (number of genomic reads / total number of reads) (r=-0.66, P<0.005) in these three 404 
experiments. The reason why this experiment indicates a low effect of treatments on the 405 
percentage of host genomic DNA and possibly its transcripts is currently unknown but 406 
might be caused by a higher rate of host genome released during the tissue preparation.  407 
 408 
In tissue homogenates spiked with higher amounts of PRRSV (50,000 TCID50/mL), 409 
although not statistically significant, statistical analyses revealed a tendency for an 410 
increase of the ratio of PRRSV reads when the two HTS experiments were taken into 411 
account (Fig. 3D; P=0.0772). Moreover, a significant variation was found in PRRSV 412 
coverage in those samples (Fig. 3E; P=0.0103) and a significant increase in PRRSV 413 
coverage in PMA treated samples without ultracentrifugation was observed (Fig. 3F; 414 
P=0.0082). Ultracentrifugation of samples containing the higher amount of PRRSV did 415 
not improve either the PRRSV number of reads or its coverage (Fig. 3D and E).  416 
 417 
In PRRSV spiked sera, there was an important increase in the ratio of PRRSV reads and 418 
coverage in untreated samples compared to results obtained with lung homogenates (Fig. 419 
3). This was in accordance with the lower amount of host genomic DNA detected in sera 420 
of untreated samples (Fig. 1B, 3iC and 5F). According to the chi-square analysis, a slight 421 
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increase in PRRSV ratio of reads was observed following PMA and EMA treatments. 422 
However, ultracentrifugation lowered the ratio of PRRSV reads when combined with 423 
EMA treatment (Fig. 3G) and was associated with a lower PRRSV coverage (Fig. 3H).  424 
 425 
3.4. High-throughput sequencing efficiency with EMA or PMA treated PRRSV positive 426 
clinical samples. 427 
 428 
In order to confirm the effectiveness of EMA and PMA treatments to increase the 429 
sensitivity of PVDA and HTS to detect viruses, both techniques were evaluated with 430 
different PRRSV positive clinical samples gathered from PRRSV experimentally infected 431 
piglets and clinical samples submitted to the MDL. All clinical samples were 432 
ultracentrifuged and treated with PMA or untreated. PMA was selected because overall, 433 
our previous findings indicated that PMA treatment was more efficient than EMA with 434 
regards to PRRSV RT-qPCR, PVDA and HTS detection.  435 
 436 
PRRSV and the amplifiable host genomic DNA copy numbers were significantly reduced 437 
in PMA treated lung tissues (Fig. 4A and Fig. 4B; P<0.001). The important PRRSV 438 
decrease in PMA treated samples was probably caused by the presence of damaged 439 
virions and/or non-encapsidated viral genomes within clinical samples. PRRSV was 440 
undetectable in all untreated samples by DNA array (Fig. 4C). Interestingly, several 441 
PRRSV probes were found positive for lung #1 in PMA treated samples (Fig. 4C; 442 
P<0.001). However, PRRSV was not detected by DNA array in lung #3 and few PRRSV 443 
probes were found positive with lung #2 following PMA treatment (Fig. 4C). For HTS 444 
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results, when the three clinical cases are taken into account together, results revealed that 445 
PMA tends to increase the number of reads obtained from lung tissues compared to 446 
untreated samples (Fig. 4D; P=0.0529). Nonetheless, PMA treatment significantly 447 
improved the percentage of PRRSV HTS reads in two out of three clinical cases tested 448 
(Fig 4D, P<0.001). Although these experiments showed an important increase in PRRSV 449 
genomic coverage (3 to 6-fold), no overall significant differences were detected (Fig. 4E; 450 
P=0.1117). No increase in PRRSV coverage was detected for lung #1 (Fig. 4E). 451 
Although lung #3 showed no increase in the percentage of PRRSV reads, an important 452 
increase (6-fold) of PRRSV coverage was detected. However, a higher host genomic 453 
DNA content is observed in this sample as suggested by the lower Ct values detected in 454 
treated and untreated sample (Fig. 4B) and the higher genomic percentage of reads (Fig. 455 
4F), compared to lungs #1 and #2.  456 
 457 
PMA treatment of clinical sera had no significant effect on amplifiable PRRSV  (Fig. 5A) 458 
or host genomeic DNA levels (Fig. 5B, Ct values >40). In agreement with spiked sera 459 
samples, PRRSV was strongly detected with all experimental conditions tested from both 460 
clinical sera samples by PVDA and HTS (Fig. 5C, D and E). However, the number of 461 
PRRSV positive probes was significantly lower in PMA treated samples for both sera 462 
samples (Fig. 5C; P<0.01). HTS results revealed that the PMA treatment also lowers the 463 
ratio of PRRSV reads in one out of two cases (Fig. 5D; P<0.001). PRRSV coverage was 464 
high in all cases (over 60%), except for serum 2 treated with PMA where the PRRSV 465 
percent of coverage was slightly higher than 40%.  466 
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4.0 Discussion and conclusion 467 
 468 
Although generally preferable, direct virus isolation and identification from clinical 469 
samples are not always possible and can sometimes lead to mis-identification of the 470 
etiological agent (29). Consequently direct identification within clinical samples, using 471 
newly available genomic technologies, is desirable. During the past decade, PVDA and 472 
HTS technologies have led to the discovery of new viruses [24-31]. However, the 473 
sensitivity of these technologies can suffer from excessive amounts of contaminating host 474 
DNA and RNA. Any methodology to decrease the masking effect that these contaminants 475 
have on viral detection is important.  476 
 477 
A new approach to lower the host genomic DNA within clinical samples is presented in 478 
this report. Our results support an increase in sensitivity of PVDA and HTS in lung tissue 479 
samples treated with PMA and, to a lesser extent, with EMA. This treatment can be done 480 
as a standalone treatment or in combination with other treatments like ultracentrifugation. 481 
Surprisingly, adding an ultracentrifugation step before the EMA or PMA treatment 482 
sometimes lowers the sensitivity of both PVDA and HTS. This is probably caused by a 483 
physical degradation of viral particles during ultracentrifugation, making these particles 484 
more sensitive to EMA or PMA treatment.  485 
 486 
Interestingly, our results indicate a higher sensitivity of PVDA and HTS with sera 487 
samples, compared to tissue homogenates. This may be explained by two phenomena. 488 
Firstly, there is a lower concentration of hg/cont in sera samples compared to tissue 489 
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homogenates, as demonstrated by β-actin DNA measurements for both untreated sera 490 
samples and tissue homogenates. Secondly, the random amplification method used to 491 
increase the amount of DNA for both HTS and PVDA techniques amplify all nucleic 492 
DNA and RNA sequences found in a sample, including hg/cont. Thus, the sensitivity of 493 
both PVDA and HTS will be highly affected by the ratio of the viral genetic material of 494 
interest over the total amount of hg/cont found in samples. This indicates that the initial 495 
amount of hg/cont in clinical samples has a deep impact on PVDA and HTS sensitivity 496 
for the identification of viruses. The variation in hg/cont content within nucleic acid 497 
extraction from clinical samples may explain the high standard deviation obtained within 498 
the results of PVDA and HTS with lung tissue homogenates spiked with the lowest 499 
PRRSV concentration. This variation can be explained by multiple factors like the 500 
extraction method, the tissue quality and the homogenization process. Also, the virus 501 
integrity in clinical samples will have to be taken into account to avoid virus particle 502 
degradation during the tissue manipulation, storage and homogenization, which can 503 
sensitize viral particles to EMA or PMA treatment. This is especially true for clinical 504 
samples where the virus type, the integrity of tissue (dead animal, sample conservation at 505 
room temperature, etc.), the amount of hg/cont or the presence of PCR inhibitors will 506 
have an critical impact on PVDA and HTS sensitivity. In addition, the efficiency of the 507 
random amplification process could be affected by the viral genome itself (its sequence 508 
and its secondary structures), making some viral genomes less compatible with the use of 509 
random amplification prior to HTS and PVDA [32]. It is important to note that our work 510 
utilized a unique virus, and does not take into account the efficiency of EMA and PMA 511 
treatments on other types of viruses. However, the outer structure of the virions of several 512 
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viruses can protect the viral genetic material from PMA treatment [19], suggesting that 513 
this treatment should reduce the influence of hg/cont when used for clinical samples with 514 
other virus types.  515 
 516 
Multiple reports have revealed differential PVDA and HTS sensitivities for viral 517 
detection and identification in clinical samples following the use of different treatment 518 
combinations, including ultracentrifugation and nuclease treatment [24, 33]. The lowest 519 
viral load in spiked serum samples was shown by Nicholson and collaborators (2011) 520 
where they determined the limit of PVDA detection for PRRSV in spiked serum samples, 521 
not subjected to nuclease treatment, to be 10,000 TCID50/mL [34]. Similar results were 522 
obtained in the present study but with lower virus concentration (5 000 TCID50/mL). 523 
 524 
Previous studies have reported the ratio of viral sequencing reads to total number of reads 525 
ranged between 0.00019% and 2.8% from non-nuclease treated serum and 526 
nasopharyngeal aspirates [25, 26]. However, Mishra and collaborators (2014) showed a 527 
ratio (viral reads/ total number of reads) of 0.00012% by HTS from muscle tissue 528 
samples [24]. In this study, rRNA was depleted and a DNase treatment was done 529 
following the RNA extraction, in order to lower hg/cont in that clinical sample [24]. 530 
These results are in accordance with our work since the percentage of PRRSV specific 531 
reads ranged between 0% and 0.00059% in spiked untreated samples and between 0% 532 
and 0.19785% in EMA and PMA-treated spiked samples. In contrast, Djikeng and 533 
collaborators (2008) have reported much higher ratios of host genomic content to isolated 534 
virus ranging between 3 and 40% [33] while Nakamura and collaborators (2009) have 535 
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reported higher genomic content ranging between 90.0% and 94.6% [26]. The variation 536 
of the host genomic DNA content between those studies is probably explained by the 537 
difference in purification and treatment methods used for each virus, like the use of 538 
gradient density centrifugation to obtained highly purified viruses with lower hg/cont 539 
[33]. The ratio of host genomic DNA content reported in our study varied between 540 
67.50% and 77.40% in untreated samples and between 40.91% and 72.76% in EMA and 541 
PMA-treated samples. This represents an improvement over the results reported by 542 
Nakamura and collaborators (2009) where no purification methods were used, and less 543 
than the ratio of hg/cont reported by Djikeng and collaborators (2008). However, in the 544 
last case, the viruses were isolated from cell culture and the virions were subsequently 545 
purified. 546 
 547 
Thus, our results indicates that EMA and PMA treatments improve the sensitivity of 548 
PVDA and HTS to detect viruses in clinical samples contaminated with hg/cont. 549 
Furthermore, EMA/PMA treatments are faster and easier to perform than a nuclease 550 
treatment. Firstly, they require shorter incubation times compared to nuclease treatment 551 
which would result in faster processing of clinical samples in a diagnostic laboratory, and 552 
should increase the robustness of the method by exerting less stress on temperature 553 
sensitive viral particles. Secondly, EMA and PMA are easy to inactivate through light 554 
exposure, subsequently leaving EMA/PMA molecules unable to destroy newly exposed 555 
viral genomic material following nucleic acid extraction, unlike the case when residual 556 
nucleases may still be present after nucleic acid purification steps. This is especially true 557 
if RNase or DNase treatment is being used in the presence of RNA or DNA viruses, 558 
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respectively. PMA/EMA treatments were more effective in tissue samples compared to 559 
sera samples which was presumably due to lower hg/cont in the latter. PMA was more 560 
effective than EMA in improving HTS and PVDA sensitivity for viral detection in 561 
clinical samples. This would be explained by the fact that EMA can leak through 562 
phospholipid bilayer membrane [35]. Moreover, ultracentrifugation appears to lower the 563 
sensitivity of HTS and PVDA following some treatments, possibly because of direct 564 
physical degradation of the viral particle. In conclusion, pre-treatment of clinical samples 565 
with EMA, and especially PMA, represents an interesting novel approach that improves 566 
PVDA and HTS sensitivity for the identification of viruses from clinical samples.  567 
 568 
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7.0. Figures legends 686 
 687 
Figure 1 688 
PRRSV and host genomic detection in spiked tissues following EMA or PMA 689 
treatment using qPCR. Effect of EMA and PMA treatments, with or without 690 
ultracentrifugation, on A) PRRSV quantification and B) host genomic DNA (β-Actin) in 691 
lung tissue homogenates spiked with PRRSV (5,000 TCID50/mL or 50,000 TCID50/mL) 692 
or in serum spiked with PRRSV (5,000 TCID50/mL). Results are expressed as Ct and 693 
were obtained from two to seven independent experiments. The results of each 694 
independent experiment (trial) are illustrated in Supplemental Figure 1.  Sample 695 
(TCID50/mL) represents the type of tissue spiked with PRRSV. Numbers in brackets 696 
represent the PRRSV concentration for each spiked sample expressed in TCID50/mL. 697 
Open bars represent results obtained from samples processed without an 698 
ultracentrifugation step while filled bars represent results obtained from samples treated 699 
with an ultracentrifugation step. A Ct value of 37 (dashed line) represents the limit of 700 
detection of each qPCR test. Labeling of two sets of data with different letters indicates 701 
that these two sets of data are statistically different (P<0.05). Sets of data using letters 702 
with the same superscript number must be compared only together.  703 
 704 
Figure 2 705 
PRRSV detection in spiked samples by DNA array following EMA or PMA 706 
treatments. DNA array probes relative intensity from A) lung tissue homogenates spiked 707 
with PRRSV (5,000 TCID50/mL), B) lung tissue homogenates spiked with PRRSV 708 
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(50,000 TCID50/mL) and C) serum samples spiked with PRRSV (5,000 TCID50/mL). 709 
Dots are relative fluorescence intensity mean values of two identical probes gathered 710 
from two to seven independent experiments (each experiment consisting of a duplicate of 711 
34 PRRSV specific probes) and was calculated as followed: [(PFL-BFL)/BFL] where 712 
PFL represents a PRRSV probe fluorescence intensity and BFL represents the basal 713 
fluorescence level (negative control probe fluorescence). The results of each independent 714 
experiment (trial) are illustrated in Supplemental Figure 2. The line represents the 715 
fluorescence mean value of all probes. Open dot circles represent results obtained from 716 
samples processed without an ultracentrifugation step while filled dot circles represent 717 
results obtained from samples treated with an ultracentrifugation step. Labeling of two 718 
sets of data with different letters indicates that these two sets of data are statistically 719 
different (P<0.05). A probe relative intensity of 1 (dashed line) represents the lowest 720 
limit of DNA array positive results.  721 
 722 
Figure 3 723 
PRRSV and host genomic detection efficiency in spiked tissue samples following 724 
EMA or PMA treatment by high-throughput sequencing. HTS results gathered from 725 
A), B) and C) lung tissue homogenates spiked with PRRSV (5,000 TCID50/mL); from D), 726 
E) and F) lung tissue homogenates spiked with PRRSV (50,000 TCID50/mL); and from 727 
G), H) and I) serum samples spiked with PRRSV (5,000 TCID50/mL). The amounts of 728 
PRRSV specific reads compared to the total number of reads gathered from each HTS 729 
run (expressed as %) are reported in panels A), D) and G) while the percentage coverage 730 
of PRRSV recovered from the total number of PRRSV specific reads are reported in 731 
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panel B), E) and H. The host genomic specific reads compared to the total number of 732 
reads gathered from each HTS run (expressed as %) are reported in panels C), F) and I). 733 
Open bars represent results obtained from samples processed without an 734 
ultracentrifugation step while filled bars represent results obtained from samples treated 735 
with an ultracentrifugation step. The results from each experiment are expressed 736 
separately in each graphic. Labeling of two sets of data with different letters indicates that 737 
these two sets of data are statistically different (P<0.05). Sets of data using letters with 738 
the same superscript number must be compared only together. The overall P-values 739 
shown in the boxes represent the statistical analysis of treatments effects taking into 740 
account all the experimental groups.  741 
 742 
Figure 4  743 
Detection of PRRSV and of host genomic DNA in clinical lung samples by RT-744 
qPCR, DNA array and high-throughput sequencing following PMA treatment. 745 
Results obtained from three clinical lung samples by A) PRRSV RT-qPCR; B) swine 746 
host genomic quantification (β-Actin) qPCR; C) DNA array; D) HTS PRRSV specific 747 
reads compared to the total amount of reads (expressed as %); E) HTS PRRSV 748 
percentage coverage recovered from the total number of PRRSV specific reads; and F) 749 
host genomic specific reads compared to the total amount of reads (expressed as %). 750 
Open bars or open circles represent results obtained from untreated samples while filled 751 
bars or filled circles represent results obtained from samples treated with PMA. A Ct 752 
value of 37 (dashed line) represents the limit of detection of each qPCR test. Dots are 753 
relative fluorescence intensity mean values of two identical probes gathered from three 754 
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independent experiments (each experiment consisting of a duplicate of 34 PRRSV 755 
specific probes) and was calculated as followed: [(PFL-BFL)/BFL] where PFL represents 756 
a PRRSV probe fluorescence intensity and BFL represents the basal fluorescence level 757 
(negative control probe fluorescence). The line represents the fluorescence mean value of 758 
all probes. A probe relative intensity of 1 (dashed line) represents the lowest limit of 759 
DNA array positive results. Results obtained from each clinical case are expressed 760 
separately in each panel. The overall P values shown in boxes represents the statistical 761 
analysis of treatments effects taking into account all the experimental groups. When two 762 
sets of data or group of data are labeled with an asterisk, it indicates that these two sets of 763 
data and group are statistically different (*** P<0.001). Labeling of two sets of data with 764 
different letters indicates that these two sets of data are statistically different (P<0.05). 765 
Only sets of data using letters with the same superscript number should be compared 766 
together.  767 
 768 
Figure 5 769 
Detection of PRRSV and of host genomic DNA in clinical sera samples by RT-770 
qPCR, DNA array and high-throughput sequencing following PMA treatment. 771 
Results obtained from two clinical serum samples by A) PRRSV RT-qPCR; B) swine 772 
host genomic quantification (β-Actin) qPCR; C) DNA array; D) HTS PRRSV specific 773 
reads compared to the total amount of reads (expressed as %); E) HTS PRRSV 774 
percentage coverage recovered from the total number of PRRSV specific reads; and F) 775 
host genomic specific reads compared to the total amount of reads (expressed as %). 776 
Open bars or open circles represent results obtained from untreated samples while filled 777 
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bars or filled circles represent results obtained from samples treated with PMA. A Ct 778 
value of 37 (dashed line) represents the limit of detection of each qPCR test. Dots are 779 
relative fluorescence intensity mean values of two identical probes gathered from two 780 
independent experiments (each experiment consisting of a duplicate of 34 PRRSV 781 
specific probes) and was calculated as followed: [(PFL-BFL)/BFL] where PFL represents 782 
a PRRSV probe fluorescence intensity and BFL represents the basal fluorescence level 783 
(negative control probe fluorescence). The line represents the fluorescence mean value of 784 
all probes. A probe relative intensity of 1 (dashed line) represents the lowest limit of 785 
DNA array positive results. The results from each clinical case are expressed separately 786 
in each panel. The overall P values shown in boxes represent the statistical analysis of 787 
treatments effects taking into account all the experimental groups. When two sets of data 788 
or group of data are labeled with an asterisk, it indicates that these two sets of data and 789 
group are statistically different (*** P<0.001; ** P<0.01). Labeling of two sets of data 790 
with different letters indicates that these two sets of data are statistically different 791 
(P<0.05). Only sets of data using letters with the same superscript number should be 792 
compared together. 793 
 794 
Supplemental Figure 1 795 
Colour coded individual trial results of PRRSV and host genome detection in spiked 796 
tissues following EMA or PMA treatment using qPCR. Effect of EMA and PMA 797 
treatments, with or without ultracentrifugation (UC), on PRRSV quantification in lung 798 
tissue homogenates spiked with A) PRRSV (5,000 TCID50/mL) or with C) PRRSV 799 
(50,000 TCID50/mL) and E) serum spiked with PRRSV (5,000 TCID50/mL); and on host 800 
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genomic DNA quantification (β-Actin) in lung tissue homogenates spiked with B) 801 
PRRSV (5,000 TCID50/mL) or with D) PRRSV (50,000 TCID50/mL) and F) serum 802 
spiked with PRRSV (5,000 TCID50/mL). Each trial identification number represents a 803 
unique experiment. All trials are the same than those illustrated in Supplemental Figure 2. 804 
Results are expressed as Ct. A Ct value of 37 (dashed line) represents the limit of 805 
detection of each the PRRSV qPCR assay. See Figure 1 for the combined statistical 806 
analyses of all trials. N.D.: not determined. 807 
 808 
Supplemental Figure 2 809 
Colour coded individual trial results of PRRSV detection in spiked samples by DNA 810 
array following EMA or PMA treatments. DNA array probes relative intensity from 811 
A) lung tissue homogenates spiked with PRRSV (5,000 TCID50/mL), B) lung tissue 812 
homogenates spiked with PRRSV (50,000 TCID50/mL) and C) serum samples spiked 813 
with PRRSV (5,000 TCID50/mL). Dots are relative fluorescence intensity mean values of 814 
two identical probes from each trials (each experiment consisting of a duplicate of 34 815 
PRRSV specific probes) and was calculated as followed: [(PFL-BFL)/BFL] where PFL 816 
represents a PRRSV probe fluorescence intensity and BFL represents the basal 817 
fluorescence level (negative control probe fluorescence). Each trial identification number 818 
represents a unique experiment. All trials are the same than those illustrated in 819 
Supplemental Figure 1. A probe relative intensity of 1 (dashed line) represents the lowest 820 
limit of DNA array positive results. See Figure 2 for combined statistical analyses of all 821 
trials. 822 
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